This session showcases the new SeptiCyte® RAPID test running on the Idylla™ platform. Learn about SeptiCyte® RAPID, a host response test, with actionable results in approximately one hour, differentiating sepsis from systemic inflammatory response syndrome (SIRS) with high negative predictive value (NPV), thus expediting and improving patient management for critically ill patients being admitted to the ICU. Steven P. LaRosa, MD, will address the challenges of current sepsis diagnosis and a new alternative approach leveraging the host immune response while Russell R® Miller III, MD, will present highlights from the VENUS study, a clinical validation of SeptiCyte® LAB.

This session was organized by Immunexpress (http://www.septicyte.com/) and presented during the Society of Critical Care Medicine’s (SCCM) 49th Critical Care Congress.

SCCM offers various sponsorship and advertising opportunities for companies to promote their brand launches or current therapies, conduct a focused program on disease awareness, or discuss their current pipeline activity.

The views, opinions, and resources expressed are those of the sponsor and do not necessarily reflect the views, opinions, or resources of SCCM. References to specific commercial entities (companies), products, tests, procedures, opinions, or other information do not reflect the review or endorsement by SCCM.